PhRMA: regulations, IP, reimbursement key for US growth
This article was originally published in SRA
Executive Summary
A strong, science-based regulatory system, coverage and payment policies that value innovative medicines, and robust intellectual property (IP) rights and enforcement in the US and abroad are among the 10 policy areas senior-level biopharmaceutical executives said are central to improving the business climate for the industry, according to a new report from Battelle1, which was commissioned by the Pharmaceutical Research and Manufacturers of America.
You may also be interested in...
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Clinton's Drug Price Plan: Threat Or Flash In The Political Pan?
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.